As 2022 draws to a close, Nevada employers should be aware of these recent developments to Nevada wage and hour laws in their preparation for 2023.
Blog
TALG’s California Employment Law Update of 2022
In California many new pieces of employment legislation were passed this year, and will take effect on January 1, 2023.
The Corporate Transparency Act: Preparing for (Potentially) Onerous Reporting Requirements
Once the Corporate Transparency Act regulations become effective it will effect corporate entities. Now is the time to prepare.
The Capital Raise – Best Practices for Biotech
Biotech and life-science companies are often in need of appropriate capital to execute the company’s mission.
The Ripple Effect of Ripple – When is a Cryptocurrency a Security?
The SEC brought an action against Ripple Labs, Inc. in a crypto-currency litigation case pending before the US District Court.
Why Traditional Mediation Methods Do Not Work
Traditional mediation today is often led by mediators who are not formally trained in the art of negotiation. As a result, their version of “mediating” is simply “splitting the pie”, often leaving both parties dissatisfied.
Clinical Trials – Protection of Human Subjects and the Role of Institutional Review Boards (IRB)
In the second part of the clinical trials series, we examine the duties and obligations of Sponsors and Clinical Research Organizations (CRO) as it relates to the protection of human subjects who participate in clinical trials.
Clinical Research Organizations (CRO) – Patient Recruitment & Privacy Considerations
In the selection of a Clinical Research Organization (CRO), the Sponsor must ensure that the CRO has careful policies and procedures in place to safeguard protected patient information.
FDA Provides GUDID Submission Requirements Guidance
FDA guidance regarding consumer health products and the enforcement of Global Unique Device Identification Database submission requirements.
FDA Issues NDA and BLA Recommendations Warranting RTOR
FDA issues guidance and recommendations for New Drug Applications (NDA) and Biologic Laboratory Applications (BLA) which implicate oncology therapies and warrant Real time Oncology Review (RTOR).